In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-08-04

AUTHORS

Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Jacques van Helden, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard

ABSTRACT

A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2 < EC50 ≤ 20 µM. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study provides information for the selection of drugs to be further validated in vivo. Disclaimer: This study corresponds to the early stages of antiviral development and the results do not support by themselves the use of the selected drugs to treat SARS-CoV-2 infection. More... »

PAGES

13093

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41598-020-70143-6

DOI

http://dx.doi.org/10.1038/s41598-020-70143-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1129847339

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32753646


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Microbiology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Betacoronavirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "COVID-19", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Caco-2 Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chlorocebus aethiops", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Coronavirus Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Approval", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation, Preclinical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Repositioning", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pandemics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pneumonia, Viral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "SARS-CoV-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Small Molecule Libraries", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vero Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Virus Replication", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005 Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.483853.1", 
          "name": [
            "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005 Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Touret", 
        "givenName": "Franck", 
        "id": "sg:person.01207573374.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207573374.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005 Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.483853.1", 
          "name": [
            "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005 Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gilles", 
        "givenName": "Magali", 
        "id": "sg:person.010164303624.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010164303624.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aix-Marseille Univ, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, CRCM, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.463833.9", 
          "name": [
            "Aix-Marseille Univ, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, CRCM, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barral", 
        "givenName": "Karine", 
        "id": "sg:person.0704242265.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704242265.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005 Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.483853.1", 
          "name": [
            "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005 Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nougair\u00e8de", 
        "givenName": "Antoine", 
        "id": "sg:person.0735102066.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735102066.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aix-Marseille Univ, INSERM, Lab. Theory and Approaches of Genome Complexity (TAGC), Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.5399.6", 
          "name": [
            "Institut Fran\u00e7ais de Bioinformatique (IFB), UMS 3601-CNRS, Universit\u00e9 Paris-Saclay, Orsay, France", 
            "Aix-Marseille Univ, INSERM, Lab. Theory and Approaches of Genome Complexity (TAGC), Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Helden", 
        "givenName": "Jacques", 
        "id": "sg:person.0626672543.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626672543.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AFMB UMR 7257, Aix-Marseille Universit\u00e9, CNRS, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.5399.6", 
          "name": [
            "AFMB UMR 7257, Aix-Marseille Universit\u00e9, CNRS, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Decroly", 
        "givenName": "Etienne", 
        "id": "sg:person.01332723167.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332723167.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005 Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.483853.1", 
          "name": [
            "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005 Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Lamballerie", 
        "givenName": "Xavier", 
        "id": "sg:person.01067672041.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067672041.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005 Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.483853.1", 
          "name": [
            "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005 Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coutard", 
        "givenName": "Bruno", 
        "id": "sg:person.01230212107.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230212107.42"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/s41586-020-2180-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1125975734", 
          "https://doi.org/10.1038/s41586-020-2180-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrmicro.2016.81", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015704176", 
          "https://doi.org/10.1038/nrmicro.2016.81"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41421-020-0156-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1125712327", 
          "https://doi.org/10.1038/s41421-020-0156-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41429-019-0204-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117973719", 
          "https://doi.org/10.1038/s41429-019-0204-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/d41573-020-00016-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1125318732", 
          "https://doi.org/10.1038/d41573-020-00016-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/d41586-020-00758-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1125734607", 
          "https://doi.org/10.1038/d41586-020-00758-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/cr.1990.1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028071262", 
          "https://doi.org/10.1038/cr.1990.1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep31819", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023183379", 
          "https://doi.org/10.1038/srep31819"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-08-04", 
    "datePublishedReg": "2020-08-04", 
    "description": "A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2\u2009<\u2009EC50\u2009\u2264\u200920\u00a0\u00b5M. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study provides information for the selection of drugs to be further validated in vivo. Disclaimer: This study corresponds to the early stages of antiviral development and the results do not support by themselves the use of the selected drugs to treat SARS-CoV-2 infection.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41598-020-70143-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.8964466", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1045337", 
        "issn": [
          "2045-2322"
        ], 
        "name": "Scientific Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "keywords": [
      "SARS-CoV-2", 
      "SARS-CoV-2 replication", 
      "SARS-CoV-2 infection", 
      "proton pump inhibitors", 
      "selection of drugs", 
      "pump inhibitors", 
      "antiarrhythmic agents", 
      "antiviral effect", 
      "therapeutic effect", 
      "Prestwick Chemical Library", 
      "CNS drugs", 
      "antiviral potency", 
      "identification of drugs", 
      "antiviral development", 
      "novel coronavirus", 
      "drugs", 
      "COVID-19", 
      "cell-based assays", 
      "drug development", 
      "EC50", 
      "inhibitors", 
      "urgent need", 
      "chemical libraries", 
      "early stages", 
      "potential inhibitors", 
      "clinic", 
      "infection", 
      "disease", 
      "different groups", 
      "CC50", 
      "study", 
      "antibiotics", 
      "FDA", 
      "coronavirus", 
      "replication", 
      "therapeutics", 
      "vivo", 
      "potency", 
      "assays", 
      "effect", 
      "group", 
      "agents", 
      "stage", 
      "screen", 
      "subset", 
      "new information", 
      "positive hits", 
      "development", 
      "compounds", 
      "panel", 
      "chemical composition", 
      "hits", 
      "need", 
      "use", 
      "molecules", 
      "information", 
      "identification", 
      "strategies", 
      "library", 
      "results", 
      "selection", 
      "China", 
      "composition", 
      "time-consuming stage", 
      "robustness", 
      "infected cell-based assay"
    ], 
    "name": "In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication", 
    "pagination": "13093", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1129847339"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41598-020-70143-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32753646"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41598-020-70143-6", 
      "https://app.dimensions.ai/details/publication/pub.1129847339"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_856.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41598-020-70143-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41598-020-70143-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41598-020-70143-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41598-020-70143-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41598-020-70143-6'


 

This table displays all metadata directly associated to this object as RDF triples.

291 TRIPLES      22 PREDICATES      118 URIs      102 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41598-020-70143-6 schema:about N07213a01fbd440bdac4431eb802335b3
2 N180a354e5a6c475682339351ba191a1c
3 N1fdcab3ee206484091f9391019453a3a
4 N2fef72f1c755439e9167859bad37c9e6
5 N35690ea3667f4da09d31b27942ba7733
6 N5e4a98ec8da740c8bac88702860329a0
7 N6724066a198a4373913a9957058f4e20
8 N99af017acd37499099df67b641e10899
9 N99dee42f83664d1c8192eb0b6d4b6749
10 Ncfb760e514304e0685fe688c68b6511f
11 Nd5c01e29d1444e20955efe7696988fe7
12 Nd70ea0c17d7d48828065202f309530d5
13 Ne24abb70f1e64af9a365eccceea580b4
14 Nefb0e1536bb04626ad3afab3468f6779
15 Nf56fbd43313a4957abd1d18c0db6fc30
16 Nf865bf058f73482db04fd3ae61dcb7b1
17 Nfe080b2fc3bb4f0d8dcaf19a988664c4
18 Nfe91bef9bd674198b57a60d40acf00d2
19 anzsrc-for:11
20 anzsrc-for:1108
21 schema:author Nc062d8c30084465eb5c06b380a9caf47
22 schema:citation sg:pub.10.1038/cr.1990.1
23 sg:pub.10.1038/d41573-020-00016-0
24 sg:pub.10.1038/d41586-020-00758-2
25 sg:pub.10.1038/nrmicro.2016.81
26 sg:pub.10.1038/s41421-020-0156-0
27 sg:pub.10.1038/s41429-019-0204-x
28 sg:pub.10.1038/s41586-020-2180-5
29 sg:pub.10.1038/srep31819
30 schema:datePublished 2020-08-04
31 schema:datePublishedReg 2020-08-04
32 schema:description A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2 < EC50 ≤ 20 µM. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study provides information for the selection of drugs to be further validated in vivo. Disclaimer: This study corresponds to the early stages of antiviral development and the results do not support by themselves the use of the selected drugs to treat SARS-CoV-2 infection.
33 schema:genre article
34 schema:inLanguage en
35 schema:isAccessibleForFree true
36 schema:isPartOf N2127edb320c14fcdaac4241d28af53cc
37 Nda38633729824790b6cbc78d2e18ce84
38 sg:journal.1045337
39 schema:keywords CC50
40 CNS drugs
41 COVID-19
42 China
43 EC50
44 FDA
45 Prestwick Chemical Library
46 SARS-CoV-2
47 SARS-CoV-2 infection
48 SARS-CoV-2 replication
49 agents
50 antiarrhythmic agents
51 antibiotics
52 antiviral development
53 antiviral effect
54 antiviral potency
55 assays
56 cell-based assays
57 chemical composition
58 chemical libraries
59 clinic
60 composition
61 compounds
62 coronavirus
63 development
64 different groups
65 disease
66 drug development
67 drugs
68 early stages
69 effect
70 group
71 hits
72 identification
73 identification of drugs
74 infected cell-based assay
75 infection
76 information
77 inhibitors
78 library
79 molecules
80 need
81 new information
82 novel coronavirus
83 panel
84 positive hits
85 potency
86 potential inhibitors
87 proton pump inhibitors
88 pump inhibitors
89 replication
90 results
91 robustness
92 screen
93 selection
94 selection of drugs
95 stage
96 strategies
97 study
98 subset
99 therapeutic effect
100 therapeutics
101 time-consuming stage
102 urgent need
103 use
104 vivo
105 schema:name In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
106 schema:pagination 13093
107 schema:productId N084e82d815f343acb37a28b47f5b52de
108 N5ef16eaf3211498d98daccfeeda102eb
109 N8a37f639c49247239242e93aeab37385
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1129847339
111 https://doi.org/10.1038/s41598-020-70143-6
112 schema:sdDatePublished 2022-01-01T18:59
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher Nfb330fbc1abc4bd6b57e5ae6650f91e1
115 schema:url https://doi.org/10.1038/s41598-020-70143-6
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N0427fbcf39f7453585f081a082c519ae rdf:first sg:person.01332723167.63
120 rdf:rest N708549accbc34eba800cc51d08904bdd
121 N07213a01fbd440bdac4431eb802335b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name COVID-19
123 rdf:type schema:DefinedTerm
124 N084e82d815f343acb37a28b47f5b52de schema:name doi
125 schema:value 10.1038/s41598-020-70143-6
126 rdf:type schema:PropertyValue
127 N180a354e5a6c475682339351ba191a1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Virus Replication
129 rdf:type schema:DefinedTerm
130 N1fdcab3ee206484091f9391019453a3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Coronavirus Infections
132 rdf:type schema:DefinedTerm
133 N2127edb320c14fcdaac4241d28af53cc schema:issueNumber 1
134 rdf:type schema:PublicationIssue
135 N2fef72f1c755439e9167859bad37c9e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Humans
137 rdf:type schema:DefinedTerm
138 N35690ea3667f4da09d31b27942ba7733 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Pandemics
140 rdf:type schema:DefinedTerm
141 N38c4b73413164942b7b348e5c12c9d89 rdf:first sg:person.01230212107.42
142 rdf:rest rdf:nil
143 N5e4a98ec8da740c8bac88702860329a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Drug Approval
145 rdf:type schema:DefinedTerm
146 N5ef16eaf3211498d98daccfeeda102eb schema:name pubmed_id
147 schema:value 32753646
148 rdf:type schema:PropertyValue
149 N6724066a198a4373913a9957058f4e20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Drug Repositioning
151 rdf:type schema:DefinedTerm
152 N685d905aed694bb69bdd92aeccc469d8 rdf:first sg:person.0735102066.96
153 rdf:rest Nb5cbaea161754cb48e94eb8028b13de2
154 N708549accbc34eba800cc51d08904bdd rdf:first sg:person.01067672041.84
155 rdf:rest N38c4b73413164942b7b348e5c12c9d89
156 N873627463b954a8e91f584fd104e6bdb rdf:first sg:person.010164303624.60
157 rdf:rest Nc5e3a59f53564229b3988c4df5a2ec0a
158 N8a37f639c49247239242e93aeab37385 schema:name dimensions_id
159 schema:value pub.1129847339
160 rdf:type schema:PropertyValue
161 N99af017acd37499099df67b641e10899 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Cell Survival
163 rdf:type schema:DefinedTerm
164 N99dee42f83664d1c8192eb0b6d4b6749 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Animals
166 rdf:type schema:DefinedTerm
167 Nb5cbaea161754cb48e94eb8028b13de2 rdf:first sg:person.0626672543.46
168 rdf:rest N0427fbcf39f7453585f081a082c519ae
169 Nc062d8c30084465eb5c06b380a9caf47 rdf:first sg:person.01207573374.33
170 rdf:rest N873627463b954a8e91f584fd104e6bdb
171 Nc5e3a59f53564229b3988c4df5a2ec0a rdf:first sg:person.0704242265.44
172 rdf:rest N685d905aed694bb69bdd92aeccc469d8
173 Ncfb760e514304e0685fe688c68b6511f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Small Molecule Libraries
175 rdf:type schema:DefinedTerm
176 Nd5c01e29d1444e20955efe7696988fe7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Pneumonia, Viral
178 rdf:type schema:DefinedTerm
179 Nd70ea0c17d7d48828065202f309530d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Vero Cells
181 rdf:type schema:DefinedTerm
182 Nda38633729824790b6cbc78d2e18ce84 schema:volumeNumber 10
183 rdf:type schema:PublicationVolume
184 Ne24abb70f1e64af9a365eccceea580b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Betacoronavirus
186 rdf:type schema:DefinedTerm
187 Nefb0e1536bb04626ad3afab3468f6779 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Drug Evaluation, Preclinical
189 rdf:type schema:DefinedTerm
190 Nf56fbd43313a4957abd1d18c0db6fc30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name SARS-CoV-2
192 rdf:type schema:DefinedTerm
193 Nf865bf058f73482db04fd3ae61dcb7b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Chlorocebus aethiops
195 rdf:type schema:DefinedTerm
196 Nfb330fbc1abc4bd6b57e5ae6650f91e1 schema:name Springer Nature - SN SciGraph project
197 rdf:type schema:Organization
198 Nfe080b2fc3bb4f0d8dcaf19a988664c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Antiviral Agents
200 rdf:type schema:DefinedTerm
201 Nfe91bef9bd674198b57a60d40acf00d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Caco-2 Cells
203 rdf:type schema:DefinedTerm
204 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
205 schema:name Medical and Health Sciences
206 rdf:type schema:DefinedTerm
207 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
208 schema:name Medical Microbiology
209 rdf:type schema:DefinedTerm
210 sg:grant.8964466 http://pending.schema.org/fundedItem sg:pub.10.1038/s41598-020-70143-6
211 rdf:type schema:MonetaryGrant
212 sg:journal.1045337 schema:issn 2045-2322
213 schema:name Scientific Reports
214 schema:publisher Springer Nature
215 rdf:type schema:Periodical
216 sg:person.010164303624.60 schema:affiliation grid-institutes:grid.483853.1
217 schema:familyName Gilles
218 schema:givenName Magali
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010164303624.60
220 rdf:type schema:Person
221 sg:person.01067672041.84 schema:affiliation grid-institutes:grid.483853.1
222 schema:familyName de Lamballerie
223 schema:givenName Xavier
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067672041.84
225 rdf:type schema:Person
226 sg:person.01207573374.33 schema:affiliation grid-institutes:grid.483853.1
227 schema:familyName Touret
228 schema:givenName Franck
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207573374.33
230 rdf:type schema:Person
231 sg:person.01230212107.42 schema:affiliation grid-institutes:grid.483853.1
232 schema:familyName Coutard
233 schema:givenName Bruno
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230212107.42
235 rdf:type schema:Person
236 sg:person.01332723167.63 schema:affiliation grid-institutes:grid.5399.6
237 schema:familyName Decroly
238 schema:givenName Etienne
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332723167.63
240 rdf:type schema:Person
241 sg:person.0626672543.46 schema:affiliation grid-institutes:grid.5399.6
242 schema:familyName van Helden
243 schema:givenName Jacques
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626672543.46
245 rdf:type schema:Person
246 sg:person.0704242265.44 schema:affiliation grid-institutes:grid.463833.9
247 schema:familyName Barral
248 schema:givenName Karine
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704242265.44
250 rdf:type schema:Person
251 sg:person.0735102066.96 schema:affiliation grid-institutes:grid.483853.1
252 schema:familyName Nougairède
253 schema:givenName Antoine
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735102066.96
255 rdf:type schema:Person
256 sg:pub.10.1038/cr.1990.1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028071262
257 https://doi.org/10.1038/cr.1990.1
258 rdf:type schema:CreativeWork
259 sg:pub.10.1038/d41573-020-00016-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125318732
260 https://doi.org/10.1038/d41573-020-00016-0
261 rdf:type schema:CreativeWork
262 sg:pub.10.1038/d41586-020-00758-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125734607
263 https://doi.org/10.1038/d41586-020-00758-2
264 rdf:type schema:CreativeWork
265 sg:pub.10.1038/nrmicro.2016.81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015704176
266 https://doi.org/10.1038/nrmicro.2016.81
267 rdf:type schema:CreativeWork
268 sg:pub.10.1038/s41421-020-0156-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125712327
269 https://doi.org/10.1038/s41421-020-0156-0
270 rdf:type schema:CreativeWork
271 sg:pub.10.1038/s41429-019-0204-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1117973719
272 https://doi.org/10.1038/s41429-019-0204-x
273 rdf:type schema:CreativeWork
274 sg:pub.10.1038/s41586-020-2180-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125975734
275 https://doi.org/10.1038/s41586-020-2180-5
276 rdf:type schema:CreativeWork
277 sg:pub.10.1038/srep31819 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023183379
278 https://doi.org/10.1038/srep31819
279 rdf:type schema:CreativeWork
280 grid-institutes:grid.463833.9 schema:alternateName Aix-Marseille Univ, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, CRCM, Marseille, France
281 schema:name Aix-Marseille Univ, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, CRCM, Marseille, France
282 rdf:type schema:Organization
283 grid-institutes:grid.483853.1 schema:alternateName Unité Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), 13005 Marseille, France
284 schema:name Unité Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), 13005 Marseille, France
285 rdf:type schema:Organization
286 grid-institutes:grid.5399.6 schema:alternateName AFMB UMR 7257, Aix-Marseille Université, CNRS, Marseille, France
287 Aix-Marseille Univ, INSERM, Lab. Theory and Approaches of Genome Complexity (TAGC), Marseille, France
288 schema:name AFMB UMR 7257, Aix-Marseille Université, CNRS, Marseille, France
289 Aix-Marseille Univ, INSERM, Lab. Theory and Approaches of Genome Complexity (TAGC), Marseille, France
290 Institut Français de Bioinformatique (IFB), UMS 3601-CNRS, Université Paris-Saclay, Orsay, France
291 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...